Article
Brochure
Executive Resource
Insight Hub
Video
Ext. PublicationNavigating the New SBIR and STTR Landscape: Opportunities and Obligations for Life Sciences Companies
Valuation Services
Never miss a thing.
Sign up to receive our insights newsletter.
A New Chapter for SBIR and STTR: More Opportunity, Higher Expectations
After a six-month lapse that disrupted funding cycles and delayed innovation pipelines, Congress has reauthorized the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2031. The renewal restores a critical source of nondilutive capital for early-stage companies across the life sciences sector. Collectively, these programs represent nearly $6 billion in annual federal funding, supporting approximately 4,000 companies each year.
That stability comes with a shift in expectations. The reauthorization reflects a more deliberate approach to how federal dollars are deployed. Agencies are placing more weight on commercialization outcomes, national security considerations and accountability for results.
SBIR and STTR awards continue to provide a path to advance programs without diluting ownership. At the same time, companies must now demonstrate a higher level of operational readiness to compete for funding.
Strategic Breakthrough Awards: Expanding the Path to Commercialization
One notable development in the reauthorization is the introduction of Strategic Breakthrough Awards. These awards are designed to support companies that are ready to move beyond early-stage research and into later stages of development or deployment.
Awards can now reach up to $30 million over multiple years. Traditional SBIR and STTR awards are significantly smaller in scale, with Phase I funding typically ranging up to approximately $300,000 and Phase II awards ranging from approximately $750,000 to more than $2 million, depending on the agency. Across the broader program, this generally results in funding at the low seven-figure level per award. The intent is to address the funding gap commonly referred to as the “valley of death,” which often emerges after Phase II when companies have validated their technology but lack sufficient capital to reach commercialization.
These awards are not an extension of early-stage experimentation. They are structured to support technologies with a clear path to real-world application. Leadership teams should evaluate whether their current programs meet these expectations, including the strength of intellectual property, progress towards regulatory milestones and alignment with agency priorities.
Fewer Submissions, Higher Stakes: What Proposal Caps Mean in Practice
The reauthorization also introduces limits on the number of Phase I and Phase II proposals a company can submit. This change responds to concerns that some organizations were submitting high volumes of applications without advancing technologies toward commercialization.
In practice, companies will have fewer opportunities to compete in each funding cycle. Leadership teams will need to be deliberate about which programs move forward and which are paused or deprioritized. This creates pressure to focus on programs with the strongest combination of scientific merit and near-term impact.
What Life Sciences Companies Should Be Doing Now
The reauthorization creates a more structured and demanding funding environment. Companies that respond proactively will be better positioned to compete.
A practical starting point is to revisit SBIR and STTR strategy in light of the changes. Larger awards are available, but competition is more focused, and expectations are higher. Companies should evaluate how these programs fit within their broader capital strategy and development timelines.
Governance and risk management also deserve renewed attention. This includes reviewing intellectual property ownership, documenting data management practices and assessing cybersecurity capabilities. Foreign relationships and affiliations should be evaluated to ensure disclosures are complete and any potential risks are understood before entering the application process.
Finally, coordination across functions is essential. Research and development, legal, IT, finance and executive leadership all play a role in meeting program requirements and presenting a cohesive application.
Weaver Can Help
The SBIR and STTR reauthorization introduces meaningful funding opportunities for life sciences companies prepared to scale. Securing and maintaining that funding now requires a higher level of preparation and coordination.
Weaver’s life sciences team works with organizations to align innovation, compliance and commercialization strategy in a changing federal funding landscape, including evaluating funding strategy, identifying readiness gaps and coordinating efforts across key business and operational functions. We help companies address requirements earlier, reduce risk during the review process and support execution once funding is secured. To learn more, contact us.
Authored by Lauren Daigle and Tyler Ridley
©2026
